An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST: START 1) [EXTENSION OF 700052699]

Trial Profile

An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST: START 1) [EXTENSION OF 700052699]

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Insulin degludec/insulin aspart (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms BOOST
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2015 Post-hoc pooled analysis results presented at the 23rd World Diabetes Congress of the International Diabetes Federation (IDF), as per Novo Nordisk media release.
    • 16 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top